Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

David A. Wilcox PhD

David A. Wilcox PhD

Associate Professor

Institution: Medical College of Wisconsin
Department: Pediatrics
Division: Hematology/Oncology
Program: Oncology


Publications

  • Integrin binding by Borrelia burgdorferi P66 facilitates dissemination but is not required for infectivity. (Ristow LC, Bonde M, Lin YP, Sato H, Curtis M, Wesley E, Hahn BL, Fang J, Wilcox DA, Leong JM, Bergström S, Coburn J) Cell Microbiol 2015 Jul;17(7):1021-36 PMID: 25604835 PMCID: PMC4478124 01/22/2015
  • In vivo enrichment of genetically manipulated platelets corrects the murine hemophilic phenotype and induces immune tolerance even using a low multiplicity of infection. (Schroeder JA, Chen Y, Fang J, Wilcox DA, Shi Q) J Thromb Haemost 2014 Aug;12(8):1283-93 PMID: 24931217 PMCID: PMC4127102 06/17/2014
  • High-level transgene expression in induced pluripotent stem cell-derived megakaryocytes: correction of Glanzmann thrombasthenia. (Sullivan SK, Mills JA, Koukouritaki SB, Vo KK, Lyde RB, Paluru P, Zhao G, Zhai L, Sullivan LM, Wang Y, Kishore S, Gharaibeh EZ, Lambert MP, Wilcox DA, French DL, Poncz M, Gadue P) Blood 2014 Jan 30;123(5):753-7 PMID: 24335497 PMCID: PMC3907760 12/18/2013
  • Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A. (Du LM, Nurden P, Nurden AT, Nichols TC, Bellinger DA, Jensen ES, Haberichter SL, Merricks E, Raymer RA, Fang J, Koukouritaki SB, Jacobi PM, Hawkins TB, Cornetta K, Shi Q, Wilcox DA) Nat Commun 2013;4:2773 PMID: 24253479 PMCID: PMC3868233 11/21/2013
  • Glanzmann thrombasthenia: state of the art and future directions. (Nurden AT, Pillois X, Wilcox DA) Semin Thromb Hemost 2013 Sep;39(6):642-55 PMID: 23929305 PMCID: PMC4011384 08/10/2013
  • Arachidonic acid-induced dilation in human coronary arterioles: convergence of signaling mechanisms on endothelial TRPV4-mediated Ca2+ entry. (Zheng X, Zinkevich NS, Gebremedhin D, Gauthier KM, Nishijima Y, Fang J, Wilcox DA, Campbell WB, Gutterman DD, Zhang DX) J Am Heart Assoc 2013 Jun;2(3):e000080 PMID: 23619744 PMCID: PMC3698766 04/27/2013
  • C560Rβ3 caused platelet integrin αII b β3 to bind fibrinogen continuously, but resulted in a severe bleeding syndrome and increased murine mortality. (Fang J, Nurden P, North P, Nurden AT, Du LM, Valentin N, Wilcox DA) J Thromb Haemost 2013 Jun;11(6):1163-71 PMID: 23551977 PMCID: PMC3702628 04/05/2013
  • Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity. (Kuether EL, Schroeder JA, Fahs SA, Cooley BC, Chen Y, Montgomery RR, Wilcox DA, Shi Q) J Thromb Haemost 2012 Aug;10(8):1570-80 PMID: 22632092 PMCID: PMC3419807 05/29/2012
  • Platelet gene therapy improves hemostatic function for integrin alphaIIbbeta3-deficient dogs. (Fang J, Jensen ES, Boudreaux MK, Du LM, Hawkins TB, Koukouritaki SB, Cornetta K, Wilcox DA) Proc Natl Acad Sci U S A 2011 Jun 7;108(23):9583-8 PMID: 21606353 PMCID: PMC3111318 05/25/2011
  • Heparin promotes platelet responsiveness by potentiating αIIbβ3-mediated outside-in signaling. (Gao C, Boylan B, Fang J, Wilcox DA, Newman DK, Newman PJ) Blood 2011 May 5;117(18):4946-52 PMID: 21368290 PMCID: PMC3100701 03/04/2011
  • TRPV4-mediated endothelial Ca2+ influx and vasodilation in response to shear stress. (Mendoza SA, Fang J, Gutterman DD, Wilcox DA, Bubolz AH, Li R, Suzuki M, Zhang DX) Am J Physiol Heart Circ Physiol 2010 Feb;298(2):H466-76 PMID: 19966050 PMCID: PMC2822567 12/08/2009
  • Developing recombinant HPA-1a-specific antibodies with abrogated Fcgamma receptor binding for the treatment of fetomaternal alloimmune thrombocytopenia. (Ghevaert C, Wilcox DA, Fang J, Armour KL, Clark MR, Ouwehand WH, Williamson LM) J Clin Invest 2008 Aug;118(8):2929-38 PMID: 18654666 PMCID: PMC2483683 07/26/2008
  • Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity. (Shi Q, Fahs SA, Wilcox DA, Kuether EL, Morateck PA, Mareno N, Weiler H, Montgomery RR) Blood 2008 Oct 1;112(7):2713-21 PMID: 18495954 PMCID: PMC2556608 05/23/2008
  • Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A. (Shi Q, Wilcox DA, Fahs SA, Fang J, Johnson BD, DU LM, Desai D, Montgomery RR) J Thromb Haemost 2007 Feb;5(2):352-61 PMID: 17269937 02/03/2007
  • Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies. (Shi Q, Wilcox DA, Fahs SA, Weiler H, Wells CW, Cooley BC, Desai D, Morateck PA, Gorski J, Montgomery RR) J Clin Invest 2006 Jul;116(7):1974-82 PMID: 16823491 PMCID: PMC1483176 07/11/2006
  • Therapeutic expression of the platelet-specific integrin, alphaIIbbeta3, in a murine model for Glanzmann thrombasthenia. (Fang J, Hodivala-Dilke K, Johnson BD, Du LM, Hynes RO, White GC 2nd, Wilcox DA) Blood 2005 Oct 15;106(8):2671-9 PMID: 15972454 PMCID: PMC1895311 06/24/2005
  • Targeting platelet GPIbalpha transgene expression to human megakaryocytes and forming a complete complex with endogenous GPIbbeta and GPIX. (Shi Q, Wilcox DA, Morateck PA, Fahs SA, Kenny D, Montgomery RR) J Thromb Haemost 2004 Nov;2(11):1989-97 PMID: 15550031 11/20/2004
  • Induction of megakaryocytes to synthesize and store a releasable pool of human factor VIII. (Wilcox DA, Shi Q, Nurden P, Haberichter SL, Rosenberg JB, Johnson BD, Nurden AT, White GC 2nd, Montgomery RR) J Thromb Haemost 2003 Dec;1(12):2477-89 PMID: 14675082 12/17/2003
  • Correction of a large animal model of type I Glanzmann's thrombasthenia by nonmyeloablative bone marrow transplantation. (Niemeyer GP, Boudreaux MK, Goodman-Martin SA, Monroe CM, Wilcox DA, Lothrop CD Jr) Exp Hematol 2003 Dec;31(12):1357-62 PMID: 14662345 12/10/2003
  • Gene therapy for platelet disorders: studies with Glanzmann's thrombasthenia. (Wilcox DA, White GC 2nd) J Thromb Haemost 2003 Nov;1(11):2300-11 PMID: 14629461 11/25/2003
  • Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatment. (Yarovoi HV, Kufrin D, Eslin DE, Thornton MA, Haberichter SL, Shi Q, Zhu H, Camire R, Fakharzadeh SS, Kowalska MA, Wilcox DA, Sachais BS, Montgomery RR, Poncz M) Blood 2003 Dec 1;102(12):4006-13 PMID: 12881300 07/26/2003
  • Expression of human factor VIII under control of the platelet-specific alphaIIb promoter in megakaryocytic cell line as well as storage together with VWF. (Shi Q, Wilcox DA, Fahs SA, Kroner PA, Montgomery RR) Mol Genet Metab 2003 May;79(1):25-33 PMID: 12765843 05/27/2003
  • Megakaryocyte-targeted synthesis of the integrin beta(3)-subunit results in the phenotypic correction of Glanzmann thrombasthenia. (Wilcox DA, Olsen JC, Ishizawa L, Bray PF, French DL, Steeber DA, Bell WR, Griffith M, White GC 2nd) Blood 2000 Jun 15;95(12):3645-51 PMID: 10845892 06/14/2000
  • Primary megakaryocytes reveal a role for transcription factor NF-E2 in integrin alpha IIb beta 3 signaling. (Shiraga M, Ritchie A, Aidoudi S, Baron V, Wilcox D, White G, Ybarrondo B, Murphy G, Leavitt A, Shattil S) J Cell Biol 1999 Dec 27;147(7):1419-30 PMID: 10613901 PMCID: PMC2174239 12/30/1999
  • Integrin alphaIIb promoter-targeted expression of gene products in megakaryocytes derived from retrovirus-transduced human hematopoietic cells. (Wilcox DA, Olsen JC, Ishizawa L, Griffith M, White GC 2nd) Proc Natl Acad Sci U S A 1999 Aug 17;96(17):9654-9 PMID: 10449749 PMCID: PMC22265 08/18/1999
  • Glanzmann thrombasthenia resulting from a single amino acid substitution between the second and third calcium-binding domains of GPIIb. Role of the GPIIb amino terminus in integrin subunit association. (Wilcox DA, Paddock CM, Lyman S, Gill JC, Newman PJ) J Clin Invest 1995 Apr;95(4):1553-60 PMID: 7706461 PMCID: PMC295643 04/01/1995
  • A single amino acid substitution flanking the fourth calcium binding domain of alpha IIb prevents maturation of the alpha IIb beta 3 integrin complex. (Wilcox DA, Wautier JL, Pidard D, Newman PJ) J Biol Chem 1994 Feb 11;269(6):4450-7 PMID: 7508443 02/11/1994
  • Developing neural crest cells in culture: correlation of cytochrome oxidase activity with SSEA-1 and dopamine-beta-hydroxylase immunoreactivity. (Liu S, Wilcox DA, Sieber-Blum M, Wong-Riley M) Brain Res 1990 Dec 10;535(2):271-80 PMID: 1981490 12/10/1990
  • Last update: 07/21/2015